Thursday, March 04, 2010
"As we learn more about the many kinds of mutations that are associated with genomic disease, so we can evaluate and model the ways that they interact to cause a phenotype."
Obstetrics/Gynecology Residents' Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome.
"Although there have been many studies regarding physicians' knowledge of hereditary cancer syndromes, very little information exists regarding medical residents' knowledge of hereditary cancer syndromes. Obstetrics/gynecology residents completed a test which evaluated their knowledge of hereditary breast and ovarian cancer and Lynch syndrome.
"The PRECEDENT study is a randomized phase 2 clinical trial comparing the company's drug EC145 in combination with pegylated liposomal doxorubicin (PLD/Doxil(R)) to PLD alone for women with platinum-resistant ovarian cancer."
Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority - MarketWatch
March 4, 2010, 1:30 a.m. EST
Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority
GOG-218 Bevacizumab Results Do Not Influence Importance of GOG-212
SEATTLE, March 4, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO(TM) used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.
Patients who question medical test results or diagnoses from their doctors should be "unafraid" to ask for a second opinion, because mistakes, although uncommon, can be made, according to the Canadian Medical Association.
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell ad
"INTRODUCTION: Paclitaxel plus carboplatin (TC) is generally considered to be the "gold standard" regimen for treatment of epithelial ovarian carcinomas. Little data are available, however, on the use of this regimen in patients with clear cell adenocarcinoma of the ovary (CCC). ...Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Progression-free survival (PFS) showed no significant difference between the 2 treatment groups. Because there were more patients with large residual disease in the CPT-P arm, we performed a subset analysis by removing those patients, and then compared the PFS with that of patients without residual disease or with residual disease less than 2 cm.
The PFS tended to be longer in the CPT-P group, although the difference was not statistically significant.
CONCLUSIONS: A phase III randomized trial is required to elucidate the effectiveness of CPT-P combination chemotherapy for CCC."
NOTE: Application deadline April 9th, 2009
Survivor Advocate Research Program Now Open! (2/22/10)
The Survivor Advocate program provides travel scholarships for 20 advocates to attend the conference, learn first-hand about key research in cancer survivorship, and to interact with other advocate leaders and survivorship researchers.
Program participants will be selected on the basis of their research advocacy experience and the potential impact conference attendance will have on their future advocacy work. Priority will be given to applicants who have not participated in the program previously.
Conference registration fees, as well as hotel and transportation costs will be covered for Survivor Advocate program participants who are selected. In addition, food expenses incurred outside of conference meals will be reimbursed"....cont'd